Cargando…
Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
Autores principales: | Shao, Hui, Guan, Dawei, Fonseca, Vivian, Shi, Lizheng, Basu, Anirban, Pop-Busui, Rodica, Ali, Mohammed K., Brown, Joshua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862367/ https://www.ncbi.nlm.nih.gov/pubmed/36099174 http://dx.doi.org/10.2337/dc22-1230 |
Ejemplares similares
-
Burden of Diabetic Peripheral Neuropathy in Pima Indians With Type 2 Diabetes
por: Jaiswal, Mamta, et al.
Publicado: (2016) -
Associations Between Oral Health Status and Diabetic Neuropathy in a Large Romanian Cohort of Patients With Diabetes
por: Jivanescu, Anca, et al.
Publicado: (2018) -
Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
por: Tseng, Chien-Wen, et al.
Publicado: (2020) -
Impact of the change of copay policy in Medicare Part D on zoster vaccine uptake among Medicare beneficiaries in a managed care organization
por: Hechter, Rulin C., et al.
Publicado: (2017) -
Patient perceptions of copay card utilization and policies
por: Cavalier, Dimika, et al.
Publicado: (2023)